Met
MET, also known as c-Met, is a receptor tyrosine kinase that functions as the cell-surface receptor for hepatocyte growth factor.
MET, also known as c-Met, is a receptor tyrosine kinase that functions as the cell-surface receptor for hepatocyte growth factor. It is an important regulator of cellular processes such as proliferation, survival, motility, invasion, and tissue remodeling. In cancer biology, MET is widely recognized as a clinically relevant oncogenic signaling node because its activation can promote tumor progression, metastatic behavior, and resistance to therapy.
Aberrant MET signaling can arise through multiple mechanisms, including gene amplification and exon 14 skipping alterations, both of which are used as molecular biomarkers in oncology. MET is therefore not only a biologically important receptor in normal physiology, but also a major therapeutic target in precision oncology, particularly in non-small cell lung cancer and other solid tumors where c-Met-directed strategies are being actively investigated.
Where the papers sit
12 papers from the last 6 months study met directly · updated from PubMed 11 Oct 2026
Study type 2 clinical trials · 1 observational · 2 human data · 5 preclinical · 2 unclassified
Themes 3 themes · 1 new direction
-
Cancer Molecular Stratification
Cancer research is moving toward molecularly defined subtypes, computational biomarkers, and treatments matched to actionable alterations. Network analysis and machine learning examine progression in colorectal cancer, while luteolin is tested against glucose uptake and malignant phenotypes in pancreatic adenocarcinoma. AI-based diagnosis targets PTPRZ1-MET fusion in secondary glioblastoma, and SMARCA2 or SMARCA4 loss defines an esophageal adenocarcinoma subtype. Telisotuzumab adizutecan extends this biomarker focus into late-line colorectal cancer treatment, though clinical benefit remains under study.
5 papers · 41.7%
-
Cross-Cancer Translational Research
Drug disposition, biopsy-based diagnosis, salvage immunotherapy, and hypoxia-selective cancer biology appear together rather than forming one disease question. Vebreltinib work tracks faecal recovery and a major circulating metabolite, while bronchoscopic profiling seeks histology and molecular profiles from small specimens. Amivantamab addresses recurrent or metastatic head and neck cancer after checkpoint inhibition and chemotherapy. ENO1 membrane localization is explored as a route to hypoxia-selective pancreatic cancer agents, with no shared therapeutic direction.
4 papers · 33.3%
-
Integrative Inflammatory Disease Biology
Multi-target pharmacology and systems analysis are being used to connect disease phenotypes with immune, microbial, and tissue-level mechanisms. Magnolia officinalis is evaluated for irritable bowel syndrome with diarrhoea, while Baitouweng decoction is compared across oral and colonic delivery in ulcerative colitis. Endometriosis analysis adds immune regulatory networks and gut microbiota-associated targets. The recurring goal is target prioritisation for complex inflammatory disorders, but the studies do not yet establish a common intervention or clinical endpoint.
3 papers · 25%
MET is proposed as a protective immune–microbiota hub in endometriosis rather than solely as a cancer-associated target
The endometriosis integrative multi-omics and network-analysis study identified MET as a hub gene with a potentially protective association, linking it to gut microbiota-derived metabolites and immune and inflammatory pathways involved in lesion formation 42713565Sep. This assigns MET a host regulatory role in a nonmalignant, hormone-dependent inflammatory disease, unlike the other papers’ use of MET as an oncogenic driver, biomarker, or therapeutic target in cancer. If validated, the finding shifts MET from being viewed only as a molecule to inhibit or detect toward a factor whose activity may help constrain disease-associated immune and microbial processes.
Papers
The 12 papers from the last 6 months that study met directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Cancer Molecular Stratification (5)
- Artificial intelligence-based diagnostic model for identifying PTPRZ1-MET fusion in a clinically defined secondary glioblastoma cohort. Molecular biomedicine · 3 Aug 2026 PMID 42547688
- SMARCA2 and SMARCA4-deficiency is associated with a distinct molecular and microenvironmental subtype of esophageal adenocarcinoma. Scientific reports · 29 Jul 2026 PMID 42527418
- Luteolin reduces glucose uptake and malignant phenotypes in pancreatic ductal adenocarcinoma cells: an integrated bioinformatics and in vitro study. Biochemical and biophysical research communications · 26 Jul 2026 PMID 42503269
- Investigating the mechanisms of malignant progression in colorectal cancer using weighted gene co-expression network analysis and machine learning. Journal of molecular histology · 18 Jul 2026 PMID 42470494
- Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 May 2026 PMID 42066233
Cross-Cancer Translational Research (4)
- Integrated prediction of lung cancer histology and molecular profiles from small bronchoscopic tumor specimens. NPJ precision oncology · 27 Jul 2026 PMID 42509268
- Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 31 May 2026 PMID 42218660
- Unravelling the human disposition of [14C]-vebreltinib: Faecal recovery of parent drug and a major circulating metabolite defines its mass balance profile. British journal of clinical pharmacology · 8 May 2026 PMID 42098960
- Identification of a Small Molecule as Potential Hypoxia-Selective Agents by Reducing Membrane Localization of ENO1 in Pancreatic Cancer Cells. Journal of medicinal chemistry · 29 Apr 2026 PMID 42053225
Integrative Inflammatory Disease Biology (3)
- Immune regulatory networks and gut microbiota-associated targets in endometriosis: an integrative multi-omics and network analysis. Open life sciences · 9 Sept 2026 PMID 42713565
- Deciphering the multi-target mechanism of Magnolia officinalis in irritable bowel syndrome with diarrhea: A combined network pharmacology, machine learning, and in vivo validation study. Biochemical and biophysical research communications · 23 May 2026 PMID 42176387
- Comparative pharmacodynamic material basis of oral and colonic administration of Baitouweng decoction in experimental ulcerative colitis. Journal of ethnopharmacology · 7 May 2026 PMID 42092473
By study type
Clinical trials (2)
- Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 31 May 2026 PMID 42218660
- Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 May 2026 PMID 42066233
Observational studies and case reports (1)
- Artificial intelligence-based diagnostic model for identifying PTPRZ1-MET fusion in a clinically defined secondary glioblastoma cohort. Molecular biomedicine · 3 Aug 2026 PMID 42547688
Human data, design not indexed (2)
- SMARCA2 and SMARCA4-deficiency is associated with a distinct molecular and microenvironmental subtype of esophageal adenocarcinoma. Scientific reports · 29 Jul 2026 PMID 42527418
- Unravelling the human disposition of [14C]-vebreltinib: Faecal recovery of parent drug and a major circulating metabolite defines its mass balance profile. British journal of clinical pharmacology · 8 May 2026 PMID 42098960
Preclinical: animal, cell and lab studies (5)
- Luteolin reduces glucose uptake and malignant phenotypes in pancreatic ductal adenocarcinoma cells: an integrated bioinformatics and in vitro study. Biochemical and biophysical research communications · 26 Jul 2026 PMID 42503269
- Investigating the mechanisms of malignant progression in colorectal cancer using weighted gene co-expression network analysis and machine learning. Journal of molecular histology · 18 Jul 2026 PMID 42470494
- Deciphering the multi-target mechanism of Magnolia officinalis in irritable bowel syndrome with diarrhea: A combined network pharmacology, machine learning, and in vivo validation study. Biochemical and biophysical research communications · 23 May 2026 PMID 42176387
- Comparative pharmacodynamic material basis of oral and colonic administration of Baitouweng decoction in experimental ulcerative colitis. Journal of ethnopharmacology · 7 May 2026 PMID 42092473
- Identification of a Small Molecule as Potential Hypoxia-Selective Agents by Reducing Membrane Localization of ENO1 in Pancreatic Cancer Cells. Journal of medicinal chemistry · 29 Apr 2026 PMID 42053225
Unclassified: not yet indexed with MeSH (2)
- Immune regulatory networks and gut microbiota-associated targets in endometriosis: an integrative multi-omics and network analysis. Open life sciences · 9 Sept 2026 PMID 42713565
- Integrated prediction of lung cancer histology and molecular profiles from small bronchoscopic tumor specimens. NPJ precision oncology · 27 Jul 2026 PMID 42509268
Written from 12 PubMed abstracts, each one listed by PMID above. Published: 2026-07-30. Last written: 2026-09-11 by GPT. Drafted by language models from published abstracts; not medical advice.